Background and importance The use of biologics is essential in the management of several
types of cancer. When patents of reference biologics expired, biosimilars emerged, widening …

Purpose The aim of this study was to assess the safety profiles of two biosimilar medicines
(rituximab and trastuzumab) in the treatment of cancer patients within a Portuguese …

Simple Summary Nowadays, biosimilar drugs are numerous and widely used in many
clinical fields, including oncology. However, skepticism remains towards these products …

Background and importance The introduction of biological drugs changed the
pharmaceutical market, improving patients 'prognoses and quality of life. Intravenous …

e14000 Background: The development of biosimilars is increasing around the world, and
facilitates patient's access to these high-tech therapies. Active pharmacovigilance is …

e14504 Background: In 2017, biosimilar trastuzumab (Zedora) became the first biosimilar
trastuzumab approved in Brazil. In May 2018 an active postmarketing surveillance program …

Background Biosimilars are highly similar to their reference products, but unlike generic
drugs, they are not identical. Differences between a biosimilar and its reference product may …

e13010 Background: Brazil has a complex health-care system which comprises 76% of
population in the public unified health system (SUS) and only 24% in private system. Even …

Background Biosimilars are additional treatment options that are approved based on robust
analytical and clinical comparisons with their reference biologic. At the time of initial …

Introduction: Innovative drugs represent the most advanced pharmacological treatment
available for patients since these drugs are characterised by a benefit and a therapeutic …